sur EUROBIO-SCIENTIFIC (EPA:ALERS)
Eurobio Scientific Gains Majority Stake Through EB Development
On 19 December 2024, Eurobio Scientific announced that EB Development now holds 88.9% of its capital, following a successful reopening of their offer. The offer attracted a total of 5,227,882 shares, including 644,911 additionally obtained after its reopening. Collaborating with NextStage AM and IK Partners, EB Development did not surpass the 90% threshold which allows for a squeeze-out, hence forgoing the additional price per share. Settlement is set for 23 December 2024.
Denis Fortier, Chairman and CEO, expressed confidence in boosting the company’s growth with NextStage and IK Partners. Eurobio Scientific is supported in its expansion strategy, notably shown in past actions like acquiring GenDx. Key shareholders and partners show unified support for Eurobio Scientific's future development phases.
NextStage's and IK Partners' involvement is expected to bolster Eurobio Scientific's leading position in the in vitro diagnostics market. They maintain commitment towards aiding entrepreneurial growth and transformation within the company.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de EUROBIO-SCIENTIFIC